Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Amoxapine
Overview
What is Amoxapine?
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines.
It is designated chemically as 2-Chloro-11-(1-piperazinyl)dibenz[][1,4]oxazepine. The structural formula is represented below:
CHCINO M.W. 313.78
Amoxapine is supplied for oral administration as 25 mg, 50 mg, 100 mg and 150 mg tablets.
Amoxapine Tablets USP, 25 mg, 50 mg, 100 mg and 150 mg contain: dibasic calcium phosphate, magnesium stearate, starch (corn), and stearic acid.
Amoxapine Tablets USP, 50 mg and 150 mg also contain: FD&C Yellow No. 6.
Amoxapine Tablets USP, 100 mg also contain: FD&C Blue No. 2.
What does Amoxapine look like?
What are the available doses of Amoxapine?
Sorry No records found.
What should I talk to my health care provider before I take Amoxapine?
Sorry No records found
How should I use Amoxapine?
Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.
Effective dosage of amoxapine may vary from one patient to another. Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily. Hospitalized patients who have been refractory to antidepressant therapy and who have no history of convulsive seizures may have dosage raised cautiously up to 600 mg daily in divided doses.
Amoxapine may be given in a single daily dose, not to exceed 300 mg, preferably at bedtime. If the total daily dosage exceeds 300 mg, it should be given in divided doses.
What interacts with Amoxapine?
Sorry No Records found
What are the warnings of Amoxapine?
Sorry No Records found
What are the precautions of Amoxapine?
Sorry No Records found
What are the side effects of Amoxapine?
Adverse reactions reported in controlled studies in the United States are categorized with respect to incidence below. Following this is a listing of reactions known to occur with other antidepressant drugs of this class.
Incidence Greater Than 1%
The most frequent types of adverse reactions occurring with amoxapine in controlled clinical trials were sedative and anticholinergic: these included drowsiness (14%), dry mouth (14%), constipation (12%), and blurred vision (7%).
Less frequently reported reactions are:
CNS and Neuromuscular:
Allergic:
Endocrine:
Gastrointestinal:
Other:
Incidence Less Than 1%
Anticholinergic:
Cardiovascular:
Allergic:
Array
Hematologic:
Gastrointestinal:
Endocrine:
Other:
Drug Relationship Unknown
The following reactions have been reported rarely, and occurred under uncontrolled circumstances where a drug relationship was difficult to assess. These observations are listed to serve as alerting information to physicians.
Anticholinergic:
Cardiovascular:
CNS and Neuromuscular:
Hematologic:
Gastrointestinal:
Endocrine:
Other:
Additional Adverse Reactions
The following reactions have been reported with other antidepressant drugs.
Anticholinergic:
CNS and Neuromuscular:
Gastrointestinal:
Endocrine:
Array
What should I look out for while using Amoxapine?
Amoxapine is contraindicated in patients who have shown prior hypersensitivity to dibenzoxazepine compounds. It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressants and monoamine oxidase inhibitors simultaneously. When it is desired to replace a monoamine oxidase inhibitor with amoxapine, a minimum of 14 days should be allowed to elapse after the former is discontinued. Amoxapine should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute recovery phase following myocardial infarction.
What might happen if I take too much Amoxapine?
How should I store and handle Amoxapine?
Care should be exercised in the handling of REVLIMID. REVLIMID capsules should not be opened or broken. If powder from REVLIMID contacts the skin, wash the skin immediately and thoroughly with soap and water. If REVLIMID contacts the mucous membranes, flush thoroughly with water.Procedures for the proper handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published. Dispense no more than a 28-day supply.Care should be exercised in the handling of REVLIMID. REVLIMID capsules should not be opened or broken. If powder from REVLIMID contacts the skin, wash the skin immediately and thoroughly with soap and water. If REVLIMID contacts the mucous membranes, flush thoroughly with water.Procedures for the proper handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published. Dispense no more than a 28-day supply.Care should be exercised in the handling of REVLIMID. REVLIMID capsules should not be opened or broken. If powder from REVLIMID contacts the skin, wash the skin immediately and thoroughly with soap and water. If REVLIMID contacts the mucous membranes, flush thoroughly with water.Procedures for the proper handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published. Dispense no more than a 28-day supply.Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015Amoxapine Tablets USP, 25 mg are 8/32", scored, round, white tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 50 mg are 10/32", scored, round, orange tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 100 mg are 11/32", scored, round, blue tablets imprinted and supplied in bottles of 100.Amoxapine Tablets USP, 150 mg are 12/32", scored, round, orange tablets imprinted and supplied in bottles of 30.Dispense in a tight container with child-resistant closure.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].Manufactured by:Watson Pharma Private LimitedVerna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised: February 2015
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor.
Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. tests show that amoxapine binding to human serum is approximately 90%.
In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides.
Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.
Non-Clinical Toxicology
Amoxapine is contraindicated in patients who have shown prior hypersensitivity to dibenzoxazepine compounds. It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressants and monoamine oxidase inhibitors simultaneously. When it is desired to replace a monoamine oxidase inhibitor with amoxapine, a minimum of 14 days should be allowed to elapse after the former is discontinued. Amoxapine should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute recovery phase following myocardial infarction.See about concurrent usage of tricyclic antidepressants and monoamine oxidase inhibitors. Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic drugs. Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. Serum levels of several tricyclic antidepressants have been reported to be significantly increased when cimetidine is administered concurrently. Although such an interaction has not been reported to date with amoxapine, specific interaction studies have not been done, and the possibility should be considered.
Drugs Metabolized by P450 2D6
The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
In prescribing the drug it should be borne in mind that the possibility of suicide is inherent in any severe depression, and persists until a significant remission occurs; the drug should be dispensed in the smallest suitable amount. Manic depressive patients may experience a shift to the manic phase. Schizophrenic patients may develop increased symptoms of psychosis; patients with paranoid symptomatology may have an exaggeration of such symptoms. This may require reduction of dosage or the addition of a major tranquilizer to the therapeutic regimen. Antidepressant drugs can cause skin rashes and/or “drug fever” in susceptible individuals. These allergic reactions may, in rare cases, be severe. They are more likely to occur during the first few days of treatment, but may also occur later. Amoxapine should be discontinued if rash and/or fever develop. Amoxapine possesses a degree of dopamine-blocking activity which may cause extrapyramidal symptoms in <1% of patients. Rarely, symptoms indicative of tardive dyskinesia have been reported.
Adverse reactions reported in controlled studies in the United States are categorized with respect to incidence below. Following this is a listing of reactions known to occur with other antidepressant drugs of this class.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).